Axe Compute Inc. applies artificial intelligence to support cancer therapy discovery and development. The company (AGPU) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Axe Compute Inc. applies artificial intelligence to support cancer therapy discovery and development. The company (AGPU) Technology Profile & Competitive Position

Axe Compute Inc. applies artificial intelligence to cancer therapy discovery, supported by a biobank of over 150,000 tumor samples. The company operates through two segments, AI-driven solutions and medical fluid waste management, positioning it at the intersection of technology and healthcare.

What Is the Investment Thesis for AGPU?

Axe Compute Inc. presents a compelling, albeit high-risk, investment thesis centered on its AI-driven approach to cancer therapy discovery and its established medical fluid waste management solutions. The company's strategic collaboration with Every Cure could unlock significant value through drug repurposing. Key value drivers include the expansion of its proprietary biobank and the increasing adoption of the STREAMWAY System. However, the company's negative profit margin of -186053.4% and small market capitalization of $123M indicate substantial financial challenges. Successful commercialization of AI-driven therapies and sustained growth in the STREAMWAY System sales are critical for long-term value creation. Investors should closely monitor the company's progress in securing partnerships, achieving regulatory milestones, and improving its financial performance.

Based on FMP financials and quantitative analysis

AGPU Key Highlights

Market capitalization of $123M reflects its small size and potential for high growth but also carries significant risk.

• Gross margin of 42.0% indicates a strong ability to control production costs in its STREAMWAY System segment.
• Profit margin of -186053.4% highlights significant challenges in achieving profitability.
• Strategic collaboration with Every Cure provides a potential catalyst for drug repurposing and revenue generation.
• Proprietary biobank of 150,000+ tumor samples offers a unique asset for AI-driven drug discovery.

Who Are AGPU's Competitors?

AGPU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AGPU's Key Strengths?

Proprietary biobank of over 150,000 tumor samples.

• FDA-cleared STREAMWAY System.
• Strategic collaboration with Every Cure.
• Expertise in AI-driven drug discovery.

What Are AGPU's Weaknesses?

Small market capitalization of $123M.

• Negative profit margin of -186053.4%.
• Limited financial resources.
• Dependence on strategic partnerships for growth.

What Could Drive AGPU Stock Higher?

Potential FDA approval of AI-discovered drug candidates.

• Expansion of the STREAMWAY System into new hospital networks.
• Progress in drug repurposing initiatives through the Every Cure collaboration.
• Development of new proprietary 3D culture models.

What Are the Key Risks for AGPU?

Financial-distress signal — its Altman Z-Score of -12.73 sits in the distress zone (elevated bankruptcy risk).

• Failure to secure additional funding for research and development.
• Competition from larger pharmaceutical companies with greater resources.
• Regulatory hurdles in obtaining FDA approval for new therapies.
• Economic downturn affecting healthcare spending and adoption of new technologies.

What Are the Growth Opportunities for AGPU?

• Expansion of AI-Driven Drug Discovery Platform: Axe Compute can capitalize on the growing market for AI in drug discovery, projected to reach $4 billion by 2028. By expanding its proprietary biobank and refining its AI algorithms, the company can accelerate the identification of promising drug candidates and secure partnerships with pharmaceutical companies. This expansion requires ongoing investment in AI infrastructure and data acquisition, but offers the potential for high-margin revenue streams.
• Increased Adoption of STREAMWAY System: The STREAMWAY System addresses a critical need for automated medical fluid waste management in hospitals and healthcare facilities. As healthcare facilities increasingly focus on efficiency and infection control, the demand for automated solutions like STREAMWAY is expected to grow. Axe Compute can drive adoption by expanding its sales and marketing efforts, targeting large hospital networks, and highlighting the system's cost-saving and safety benefits.
• Strategic Partnerships for Drug Repurposing: Axe Compute's collaboration with Every Cure presents a significant opportunity to identify and prioritize drugs for repurposing. By leveraging its AI platform and biobank, the company can accelerate the drug repurposing process and potentially generate revenue through licensing agreements or co-development partnerships. The success of this initiative depends on the effectiveness of the AI algorithms and the ability to secure favorable terms with pharmaceutical partners.
• Development of Proprietary 3D Culture Models: The company's proprietary 3D culture models offer a valuable tool for drug development, providing a more realistic and predictive environment for testing drug candidates. By expanding its portfolio of 3D culture models and offering customized solutions to pharmaceutical companies, Axe Compute can generate revenue through service contracts and licensing agreements. This growth opportunity requires ongoing investment in research and development to maintain a competitive edge.
• Geographic Expansion of STREAMWAY System Sales: Currently focused on the US market, Axe Compute can explore opportunities to expand the sales of its STREAMWAY System to international markets. By targeting countries with advanced healthcare systems and a focus on infection control, the company can tap into new revenue streams and diversify its customer base. This expansion requires careful market research, regulatory approvals, and the establishment of distribution networks.

What Are AGPU's Competitive Advantages?

• Proprietary biobank of over 150,000 tumor samples provides a unique data asset for AI-driven drug discovery.
• FDA-cleared STREAMWAY System offers a competitive advantage in the medical fluid waste management market.
• Strategic collaboration with Every Cure enhances its capabilities in drug repurposing.
• Expertise in applying AI to cancer therapy discovery provides a technological edge.

What Does AGPU Do?

Axe Compute Inc., formerly Predictive Oncology Inc., is a knowledge and science-driven company established in 2002 and headquartered in Pittsburgh, Pennsylvania. The company rebranded in December 2025 to reflect its sharpened focus on artificial intelligence applications. Axe Compute operates through two primary segments: Pittsburgh and Eagan. The Pittsburgh segment is dedicated to applying AI to support the discovery and development of cancer therapies, leveraging a proprietary biobank containing over 150,000 tumor samples. This segment also develops proprietary 3D culture models utilized in drug development. The Eagan segment focuses on producing the FDA-cleared STREAMWAY System and associated products, which provide automated medical fluid waste management and patient-to-drain medical fluid disposal solutions. Axe Compute Inc. has a strategic collaboration with Every Cure, aimed at identifying and prioritizing drugs for repurposing, further solidifying its commitment to innovative healthcare solutions. The company's evolution reflects a strategic shift towards AI-driven healthcare advancements, positioning it as a key player in the intersection of technology and oncology.

What Products and Services Does AGPU Offer?

• Applies artificial intelligence to support the discovery and development of cancer therapies.
• Operates a proprietary biobank of over 150,000 tumor samples.
• Creates proprietary 3D culture models used in drug development.
• Produces the FDA-cleared STREAMWAY System for automated medical fluid waste management.
• Provides patient-to-drain medical fluid disposal solutions.
• Collaborates with Every Cure to identify and prioritize drugs for repurposing.

How Does AGPU Make Money?

• AI-driven drug discovery services, generating revenue through partnerships and licensing agreements.
• Sales of the STREAMWAY System and associated products for medical fluid waste management.
• Development and licensing of proprietary 3D culture models for drug development.
• Strategic collaborations for drug repurposing, potentially generating revenue through licensing or co-development.

What Industry Does AGPU Operate In?

Axe Compute Inc. operates within the rapidly evolving software and infrastructure sector, specifically targeting the intersection of AI and healthcare. The market for AI in drug discovery is experiencing substantial growth, driven by the increasing need for faster and more efficient drug development processes. The competitive landscape includes established pharmaceutical companies and emerging biotech firms leveraging AI. Axe Compute's focus on a proprietary biobank and strategic collaborations positions it as a niche player with potential for significant impact, contingent on successful commercialization and market adoption.

Who Are AGPU's Key Customers?

• Pharmaceutical companies seeking to accelerate drug discovery and development.
• Hospitals and healthcare facilities requiring automated medical fluid waste management solutions.
• Research institutions utilizing 3D culture models for drug testing.
• Organizations involved in drug repurposing initiatives.

Axe Compute Inc. applies artificial intelligence to support cancer therapy discovery and development. The company (AGPU) Valuation Context

Valued at $123M, AGPU is classified as a micro-cap stock. Relative to its peer group, AGPU's quantitative score of 12/100 is below the peer average of 73/100.

AGPU Revenue & Earnings Trend

In Q2 2026, AGPU generated $3.2M in top-line revenue, marking a sequential increase of 9004.8%. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Technology company. Across the four most recent quarters, AGPU averaged $-36.36 in diluted EPS.

Company Profile

Axe Compute Inc. applies artificial intelligence to support cancer therapy discovery and development. The company operates in the Software - Infrastructure industry within the Technology sector. It is headquartered in Pittsburgh, US. The company is led by CEO Christopher Miglino. AGPU has traded publicly since 2010.

Key Financial Metrics

Its free cash flow yield is -47.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.89 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -146.5%, the inverse of the P/E and a quick read on earnings relative to price.

Axe Compute Inc. applies artificial intelligence to support cancer therapy discovery and development. The company's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -12.73 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Axe Compute Inc. applies artificial intelligence to support cancer therapy discovery and development. The company revenue of about $15.4M for fiscal 2026, with EPS near $1.20.

AGPU Financials

AGPU Latest News

AGPU Analyst Consensus

AGPU MoonshotScore

Axe Compute Inc. applies artificial intelligence to support cancer therapy discovery and development. The company Technology Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources